Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stefan Dübel1, Andreas Herrmann2, Thomas Schirrmann2,3

  • 1Abteilung Biotechnologie, Institut für Biochemie, Biotechnologie und Bioinformatik, Technische Universität Braunschweig, Spielmannstraße 7, D-38106 Braunschweig, Deutschland.

Biospektrum : Zeitschrift Der Gesellschaft Fur Biologishe Chemie (GBCH) Und Der Vereinigung Fur Allgemeine Und Angewandte Mikrobiologie (VAAM)
|February 22, 2021
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The landscape of antibody production systems: recombinant expression for research, diagnostics and therapy.

Frontiers in bioengineering and biotechnology·2026
Same author

Novel bispecific T-cell engagers overcoming acquired EGFR resistance.

mAbs·2026
Same author

Phase I Study Evaluating a Monoclonal Fc-Silenced SARS-CoV-2 Antibody in Patients With Moderate-to-Severe COVID-19.

Clinical therapeutics·2026
Same author

A pH-sensitive binding modality allows successful transferrin receptor-mediated transcytosis of a bivalent antibody across brain barriers.

mAbs·2025
Same author

Evaluation of the Neutralizing Antibody STE90-C11 against SARS-CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns.

Viruses·2023
Same author

Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.

Frontiers in immunology·2023
Same journal

Biospektrum : Zeitschrift der Gesellschaft fur Biologishe Chemie (GBCH) und der Vereinigung fur Allgemeine und Angewandte Mikrobiologie (VAAM)·2023
Same journal

Biospektrum : Zeitschrift der Gesellschaft fur Biologishe Chemie (GBCH) und der Vereinigung fur Allgemeine und Angewandte Mikrobiologie (VAAM)·2023
Same journal

Biospektrum : Zeitschrift der Gesellschaft fur Biologishe Chemie (GBCH) und der Vereinigung fur Allgemeine und Angewandte Mikrobiologie (VAAM)·2023
Same journal

Biospektrum : Zeitschrift der Gesellschaft fur Biologishe Chemie (GBCH) und der Vereinigung fur Allgemeine und Angewandte Mikrobiologie (VAAM)·2023
Same journal

Biospektrum : Zeitschrift der Gesellschaft fur Biologishe Chemie (GBCH) und der Vereinigung fur Allgemeine und Angewandte Mikrobiologie (VAAM)·2023
Same journal

Biospektrum : Zeitschrift der Gesellschaft fur Biologishe Chemie (GBCH) und der Vereinigung fur Allgemeine und Angewandte Mikrobiologie (VAAM)·2023
See all related articles

A novel antibody, COR-101, significantly reduced SARS-CoV-2 lung virus load by over 99% in hamster models, accelerating recovery. Its mechanism involves blocking the spike protein

Area of Science:

  • Immunology
  • Virology
  • Structural Biology

Context:

  • Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection poses a significant global health threat.
  • Development of effective antiviral therapies remains a critical research area.
  • Antibody-based therapeutics offer a promising strategy for combating viral infections.

Purpose:

  • To characterize the efficacy and mechanism of action of COR-101, a novel fully human, Fc-silenced IgG antibody.
  • To evaluate the therapeutic potential of COR-101 against SARS-CoV-2 infection in a preclinical model.

Summary:

  • COR-101, identified via antibody phage display, demonstrated over 99% reduction in SARS-CoV-2 lung viral load in hamster models.
  • The antibody facilitated significantly faster recovery in infected hamsters.

Related Experiment Videos

  • Structural analysis revealed COR-101's mode of action: it competitively inhibits ACE2 binding by blocking a substantial region of the SARS-CoV-2 spike protein.

    • Impact:

    • COR-101 exhibits potent antiviral activity against SARS-CoV-2, suggesting its potential as a therapeutic agent.
    • Understanding the structural basis of its interaction provides insights for designing next-generation antiviral antibodies.
    • This research contributes to the ongoing efforts to develop effective treatments for COVID-19.